Hepatic Transcriptome Analysis of Hepatitis C Virus Infection in Chimpanzees Defines Unique Gene Expression Patterns Associated with Viral Clearance Authors: Santosh Nanda, Michael B. Havert, Gloria M. Calderón, Michael Thomson, Christian Jacobson, Daniel Kastner, T. Jake Liang Published: 2008, PLOS ONE DOI: 10.1371/journal.pone.0003442 ABSTRACT Hepatitis C virus infection leads to a high rate of chronicity. Mechanisms of viral clearance and persistence are still poorly understood. In this study, hepatic gene expression analysis was performed to identify any molecular signature associated with the outcome of hepatitis C virus (HCV) infection in chimpanzees. Acutely HCV-infected chimpanzees with self-limited infection or progression to chronicity were studied. Interferon stimulated genes were induced irrespective of the outcome of infection. Early induction of a set of genes associated with cell proliferation and immune activation was associated with subsequent viral clearance. Specifically, two of the genes: interleukin binding factor 3 (ILF3) and cytotoxic granule-associated RNA binding protein (TIA1), associated with robust T-cell response, were highly induced early in chimpanzees with self-limited infection. Up-regulation of genes associated with CD8+ T cell response was evident only during the clearance phase of the acute self-limited infection. The induction of these genes may represent an initial response of cellular injury and proliferation that successfully translates to a “danger signal” leading to induction of adaptive immunity to control viral infection. This primary difference in hepatic gene expression between self-limited and chronic infections supports the concept that successful activation of HCV-specific T-cell response is critical in clearance of acute HCV infection. INTRODUCTION Since the identification of hepatitis C virus (HCV) in the late 1980s, HCV infection has been recognized as a growing public health problem in the world. It is estimated that about 200 million people are chronically infected [1] . No HCV vaccines are available to date and only a subset of patients respond to current interferon-based treatment [1] . Much research effort has been focused on understanding the mechanisms of infection, persistence and clearance of HCV. Studies on hepatic gene expression in chimpanzees and humans have revealed intriguing differences between acute resolving and chronic HCV infections [2] – [6] . In the chimpanzee model, HCV infection induces type I IFN response and activation of a large number of interferon stimulated genes (ISGs) in the liver [2] , [6] , [7] . However, hepatic induction of type I IFN occurred in all animals irrespective of the outcome of infection [6] , [8] . Thus, type I IFN may restrict excessive viral replication in the early phase of infection but does not seem to play a major role in subsequent viral clearance. Similar to experimentally infected chimpanzees, gene expression analysis of percutaneous liver biopsies in HCV infected humans demonstrated increased ISG expression, suggesting an ongoing host cellular response to viral infection [4] . It is not well understood why HCV is not cleared from these individuals despite the activation of potent antiviral ISGs. It is possible that in these individuals with viral persistence, the cellular response to IFN is inefficient compared to those who clear the virus. Weak induction of the ISG antiviral state coupled with an ineffective cellular immune response could therefore promote chronicity [3] . Studies of temporal changes in gene expression are central to understanding viral clearance, persistence and hepatic injury in chronic HCV infection. The intrahepatic T cell response to HCV correlates with control of acute infection [7] . Cytokine and immunomodulatory genes, generally known to be chemotactic and/or stimulatory to various immune cells were observed to be induced within the first 6 to 8 weeks after infection [2] . Viral clearance is associated with a vigorous HCV-specific T-cell response in the liver with both cytotoxic and non-cytotoxic effector functions. However HCV persists in the majority of acutely infected patients. The mechanisms leading to the failure of HCV-specific T-cell response and viral persistence are highly complex and still not fully understood. Therefore it is important to compare the spectrum and magnitude of hepatic gene expression in individuals who spontaneously clear infection and those who progress to chronicity. In this study we examined the host response to HCV infection by applying gene expression profiling of serial liver biopsies during acute HCV infection and identified unique gene expression patterns that are associated with specific outcomes of infection. RESULTS To identify differentially expressed hepatic genes associated with early stages of HCV infection, a database of expression levels was generated and queried for genes whose expression was outside a calculated 99% confidence interval at different times. Using this confidence interval, 1% of genes with the greatest-fold change or least-fold change are defined as significantly up- or down-regulated (see Materials and Methods ). For chimpanzee X0190 with self-limited infection, 347 genes were induced above the confidence interval (>1.9-fold change) at 4 weeks post-infection. Some of the induced genes were related to antiviral and/or type I interferon response, consistent with ongoing HCV infection. To refine our search and to further identify genes specifically associated with the early phase of infection, the database of expression levels for X0190 was queried again for genes above the confidence interval at two time points, weeks 4 and 6 post-infection (>1.9- and >2.1-fold induction), and below the confidence interval at weeks 13 and 40 (<2.2-, and <2.4-fold induction) when the chimpanzee had cleared the infection. By using these criteria, 22 genes were significantly up-regulated, 9 of which are known to be induced by type I interferon ( Table 1 ). The remaining 13 genes are classified as Cellular Immune Response Related or Cell Growth/Signal Transduction Related. Expression levels of genes induced above the confidence interval at weeks 4 & 6 but below the confidence interval at weeks 13 & 40 in X0190. The bold and italicized values represent data above the 99% confidence interval as described in the text. TABLE: Genes induced during the early phase of self-limited and persistent infections. Type I Interferon Response Chimp X0190 a Chimp X0234 Chimp X0142 Title Clone description UG cluster wk 4 wk 6 wk 13 wk 40 wk 6 wk 8 wk 10 wk 12 wk 6 wk 8 wk 10 wk 12 wk 60 wk 68 wk 89 wk 101 G1P2 Interferon-stimulated protein (15 kDa) Hs. 432233 8.1 4.6 0.5 0.3 3.1 7.9 1.5 0.5 7.4 14 6.7 1.5 7.5 7.4 11 15 IFI27 Interferon alpha-inducible protein 27 Hs. 278613 6.6 4.4 0.6 0.3 3.5 7.1 1.5 0.6 6.6 14 6.6 1.4 6.7 6.6 11 14 OAS3 2′-5′oligoadenylate synthetase 3 Hs. 56009 5.5 5.3 1.4 0.5 3.2 2.3 1.1 0.8 4.5 4.5 2.0 1.1 4.7 4.5 4.8 4.5 GIP3 Interferon alpha-inducible protein (clone IFI-6-16) Hs. 265827 4.0 3.8 0.7 0.3 0.8 5.3 2.2 0.6 4.3 5.0 2.5 1.4 5.8 4.3 4.7 5.0 IFIT1 Interferon-induced protein w/tetratricopeptide repeat Hs. 20315 3.8 2.8 0.6 0.9 3.2 6.4 0.9 0.5 4.3 4.9 6.6 0.6 6.8 4.3 5.3 4.9 MX1 Myxovirus (influenza) resistance 1 Hs. 48516 3.6 3.8 1.0 0.7 3.1 2.8 1.0 1.5 3.4 2.8 1.8 0.8 4.2 3.4 3.7 2.8 B2M Beta-2-microglobulin Hs. 75415 3.2 2.2 1.4 2.0 0.8 3.9 2.4 0.6 2.3 2.2 2.2 1.2 2.5 2.3 2.4 2.2 OAS2 2′-5′oligoadenylate synthetase 2 Hs. 432659 2.7 2.2 1.0 0.8 2.0 2.0 1.1 1.1 3.2 2.2 2.1 1.3 1.1 1.3 0.9 1.1 SP110 Interferon-induced protein 75 (52 kD) Hs. 38125 2.7 2.3 1.3 0.7 1.4 0.9 1.3 0.8 1.8 1.3 1.3 1.3 3.3 3.2 2.4 2.2 Cellular Immune Response ILF3 Interleukin enhancer binding factor 3, 90 kD Hs. 56583 3.0 2.3 1.6 0.8 1.5 0.9 1.7 1.1 1.3 1.1 0.7 1.1 1.1 1.3 0.9 1.1 TIA1 Cytotoxic granule-associated RNA-binding protein Hs. 39489 2.6 2.2 2.1 1.0 1.3 0.6 1.1 1.1 1.2 1.2 0.7 2.0 1.2 1.2 1.4 1.2 Cell Growth/Signal Transduction FOSB FBJ murine osteosarcoma viral oncogene homolog B Hs. 75678 10 5.4 0.4 0.3 0.7 0.4 0.4 0.7 1.2 0.6 0.6 0.6 0.8 1.2 1.1 0.6 SMARCB Actin dependent regulator of chromatin (SWI/SNF related) Hs. 59971 7.9 4.5 0.6 0.5 1.1 1.1 1.0 0.9 1.7 0.8 0.9 0.8 1.5 1.7 1.3 0.8 ITGA6 Integrin alpha 6 Hs. 27730 6.6 3.4 1.4 0.6 0.7 1.2 1.3 1.3 1.7 1.3 1.3 1.2 1.9 1.7 1.9 1.3 JUN v-jun avian sarcoma virus 17 oncogene homolog Hs. 78465 4.7 3.3 0.3 0.6 0.9 0.9 1.0 0.9 1.5 0.6 0.6 0.9 0.8 1.5 0.7 0.6 PRNP Prion protein (p27–30) Hs. 74621 3.6 2.1 2.1 2.0 0.7 1.7 1.3 0.6 1.4 0.5 1.0 0.8 1.1 1.4 0.7 0.5 ID2 Inhibitor of DNA binding 2 Hs. 180919 3.1 2.2 0.5 0.6 0.6 0.9 0.7 0.8 2.1 1.3 1.2 1.3 2.4 2.1 1.7 1.3 JUNB Jun B proto-oncogene Hs. 400124 3.0 2.8 1.7 1.3 1.1 0.8 1.0 1.3 2.3 2.4 0.9 1.3 1.8 2.3 1.6 2.4 TOB2 Transducer of ERBB2 Hs. 4994 2.8 2.3 1.9 0.6 1.9 1.4 1.7 2.3 2.1 1.6 1.2 1.7 2.6 2.1 1.7 1.6 PRSS21 Serine protease, 21 (testisin) Hs. 72026 2.5 2.5 1.6 1.0 2.3 2.2 1.8 1.7 2.7 2.6 2.9 1.4 2.1 2.7 2.6 2.6 TRB2 GS3955 protein Hs. 55418 2.1 2.2 1.8 1.1 1.0 1.5 1.7 1.6 1.9 1.5 1.5 1.5 1.2 1.9 1.5 1.5 ARHD Ras homolog gene family, member Hs. 15114 2.0 2.4 0.8 0.8 0.9 0.8 0.9 1.1 1.3 0.9 0.9 0.9 0.9 1.3 1.1 0.9 Confidence interval 1.9 2.1 2.2 2.4 2.5 2.0 2.6 2.4 2.5 2.0 2.6 2.4 2.2 2.5 1.9 2.0 COMPARISON OF HEPATIC GENE EXPRESSION DURING SELF-LIMITED AND PERSISTENT INFECTIONS To determine whether a different pattern of gene expression is observed between infected chimpanzees in this subset of genes, biopsy samples from two persistently infected chimpanzees X0234 and X0142 were compared to chimpanzee X0190 ( Table 1 ). Within the first 8 weeks of infection, a large number of type I interferon stimulated genes (ISGs) were strongly up-regulated in all chimpanzees. Type I interferon induced genes are the first line of innate defense against viral infection and also function to prime and modulate adaptive immune response. A qualitative or quantitative difference of ISG induction could not be correlated with persistence or clearance. However several genes related to cellular immune response and cell growth/signal transduction, such as ILF3, TIA1, FOSB, JUN, ID2, were differentially induced in chimpanzee X0190. At later time points for X0190, none of the type I interferon response genes were significantly upregulated, consistent with the clearance of viremia and resolution of infection. Interestingly, a similar gene expression pattern was also observed for the persistently infected chimps. In X0234, some of these genes that were induced earlier returned to baseline at week 10, but became elevated again at week 12 post-infection. It has been shown that acutely infected chimpanzees and humans can have markedly fluctuating levels of viremia during the acute phase, possibly indicating transient control of viral infection [9] – [11] . This transient control could explain the lack of continuous induction of ISGs at certain time points. In particular, the viral level of X0234 at week 8 was 4000 genomes/mL, week 10 was 600 genomes/mL (borderline detection), and week 12 was 7000 genomes/mL. Additional biopsy samples from one of these animals, X0142, were collected at much later time points during the chronic phase ( Fig. 1 ). Up-regulation of many ISGs was again observed, suggesting the establishment of chronic infection. This observation is consistent with previous publications [3] , [6] . Chimpanzees were inoculated with RNA transcript of the molecular clone HCV-CG1b or infectious serum from the same clone (○). The course of infection has been described previously (Thomson et al., 2001). The level of viremia is shown as either positive (+) negative (−). Biopsy samples were taken at various time points after inoculation (↓) and used for microarray analysis X0190, X0234 and X0142). RNA samples from weeks 8 and 10 of X0190 were not of adequate quality for microarray analysis. As an alternative approach to identify genes induced during the early stage of infection that could be associated with clearance, the average expression profile of persistently infected chimpanzees (X0234 and X0140) was compared to the average expression profile of chimp X0190 during weeks 4 and 6. We reasoned that any difference between the two groups of animals, if significant, might be more easily detected by averaging the gene expression values during this time frame. Furthermore, we might identify a different set of induced genes compared to our previous analysis (e.g. genes whose fold-induction levels were within the confidence interval for at least one time point but were on average higher during the acute phase of infection). During the first eight weeks of self limited infection (X1090) we found 36 known genes induced 2.5-fold or greater over those during persistent infection (X0234 and X0140). The averaged ratios of induction are shown in Table 2 . Six of these genes were also found on the list of the previous analysis of chimpanzee X0190 at weeks 4 and 6 ( Table 1 ). Average expression values of biopsies taken during the 1 st 8 weeks of infection. Bold-face genes are also in Table 1 . TABLE: Genes induced during the early phase of self-limited infection as defined by average expression values. Title Clone description UG cluster Self-limited infection a Persistent infection a Ratio of induction FOSB FBJ murine osteosarcoma viral oncogene homolog B Hs.75678 7.54 0.77 9.77 DCT Dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-related protein 2) Hs.301865 6.55 0.69 9.44 SMARCB Actin dependent regulator of chromatin (SWI/SNF related) Hs.159971 6.04 0.64 9.41 EGR1 Early growth response 1 Hs.738 2.50 0.30 8.20 ETR101 Immediate early protein Hs.737 8.02 1.19 6.75 RPS4Y Ribosomal protein S4, Y-linked Hs.180911 8.46 1.40 6.02 JUN v-jun avian sarcoma virus 17 oncogene homolog Hs.78465 3.99 0.76 5.21 CYP1A1 Cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1 Hs.72912 2.18 0.48 4.51 SCYA3 Small inducible cytokine A3 (homologous to mouse Mip-1a) Hs.73817 1.23 0.29 4.28 PEX1 Peroxisome biogenesis factor 1 Hs.99847 3.68 0.90 4.09 KIAA0855 Golgin-67 Hs.182982 2.01 0.54 3.75 SARS Seryl-tRNA synthetase Hs.4888 1.13 0.31 3.68 GLO1 Glyoxalase I Hs.75207 4.14 1.14 3.63 ITGA6 Integrin alpha 6 Hs.227730 4.79 1.35 3.55 DUSP1 Dual specificity phosphatase 1 Hs.171695 2.31 0.68 3.41 PRNP Prion protein (p27–30) Hs.74621 2.79 0.87 3.21 RUVBL2 RuvB (E coli homolog)-like 2 Hs.6455 1.80 0.58 3.10 SCYA3L1 Small inducible cytokine A3-like 1 Hs.274535 0.97 0.31 3.10 TRF4 Topoisomerase-related function protein 4-1 Hs.225951 1.73 0.57 3.03 CALML3 Calmodulin-like 3 Hs.239600 2.96 1.01 2.94 GCN1L1 GCN1 (general control of amino-acid synthesis 1, yeast)-like 1 Hs.75354 1.58 0.55 2.89 SCD Stearoyl-CoA desaturase (delta-9-desaturase) Hs.119597 1.16 0.40 2.88 ATP2B2 ATPase, Ca++ transporting, plasma membrane 2 Hs.89512 1.40 0.49 2.86 CYP4F3 Cytochrome P450, subfamily IVF, polypeptide 3 (leukotriene B4 omega hydroxylase) Hs.106242 2.94 1.05 2.80 COL7A1 Collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive) Hs.1640 1.58 0.57 2.78 SLC6A3 Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 Hs.406 2.57 0.95 2.70 KLF4 Kruppel-like factor 4 (gut) Hs.7934 2.23 0.83 2.67 ILF3 Interleukin enhancer binding factor 3, 90 kD Hs.256583 2.63 1.00 2.62 ID2 Inhibitor of DNA binding 2 Hs.180919 2.64 1.02 2.58 ZNF216 Zinc finger protein 216 Hs.3776 1.07 0.41 2.57 NR1I2 Nuclear receptor subfamily 1, group I, member 2 Hs.118138 1.89 0.74 2.56 TIA1 TIA1 cytotoxic granule-associated RNA-binding protein Hs.239489 2.40 0.94 2.56 CDK9 Cyclin-dependent kinase 9 (CDC2-related kinase) Hs.150423 1.66 0.66 2.52 RELA v-rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypepti Hs.75569 1.79 0.71 2.52 EPHX2 Epoxide hydrolase 2, cytoplasmic Hs.113 2.50 1.00 2.51 CYP4F2 Cytochrome P450, subfamily IVF, polypeptide 2 Hs.101 1.99 0.79 2.51 HEPATIC GENE EXPRESSION DURING THE CLEARANCE PHASE OF SELF-LIMITED INFECTION To identify genes that may be specifically induced during viral clearance in chimpanzee X0190, the database of expression levels was queried for genes above the confidence interval at 13 weeks post-infection (>2.2-fold induction) and below this interval at 4, 6 and 40 weeks (<1.9-, 2.1-, and 2.4-fold induction). Forty-four genes were significantly up-regulated at 13 weeks ( Table 3 ). Twenty of these were associated with activation of cellular immunity and as such were classified as Cellular Immune Response-related. Consistent with the previous observation of active HCV-specific T-cell response in biopsy specimens during resolving infections, we found evidence for a vigorous immune response involving induction of CD8+ T-cell markers (CD8 antigen and components of the T-cell receptor) and effectors of CD8+ T cells (granzyme A and interferon-gamma) in X0190. The remaining 25 genes significantly induced at 13 weeks could be classified as Cell Growth/Signal Transduction-related ( Table 3 ). Expression levels of genes induced above the confidence interval at week 13 but below the confidence interval at weeks 4, 6 & 40 of X0190. The bold and italicized values represent data above the 99% confidence interval as described in the text. To discern additional differences between the self-limited and chronically infected chimpanzees, the averaged expression profiles of the two persistently infected chimpanzees (X0142 and X0234) from weeks 10 to 12 were compared to those of chimpanzee X0190 during clearance (week 13). We reason that viral clearance may be associated with a distinct set of gene expression in the liver. By comparing the gene expression profiles at about the same time when the chimpanzee is undergoing viral clearance to those of chimpanzee who is not could provide valuable insight into the mechanism of viral clearance. During this phase, 20 known genes of X0190 were induced 2.5-fold or greater over the average values of the equivalent time points of X0142 and X0234 ( Table 4 ). Of these, 5 genes are also in Table 3 . Expression value of biopsy taken at 13 weeks of infection. Average expression values of biopsies taken during the 10 and 12 weeks of infection. Bold-face genes are also in Table 1 . TABLE: Genes induced during the clearance phase of self-limited infection. Cellular Immune Response Chimp X0190 a Chimp X0234 Chimp X0142 Title Clone description UG cluster wk 4 wk 6 wk 13 wk 40 wk 6 wk 8 wk 10 wk 12 wk 6 wk 8 wk 10 wk 12 wk 60 wk 68 wk 89 wk 101 GZMA Granzyme A Hs.90708 1.3 1.7 6.5 1.5 1.2 2.5 1.8 1.7 5.6 1.3 2.5 4.7 1.7 5.6 2.2 1.3 CD3D CD3D antigen, delta polypeptide Hs.95327 1.7 2.0 6.4 2.0 1.3 2.7 2.4 1.7 3.9 1.2 1.7 3.6 2.5 3.9 2.1 1.2 IGL Immunoglobulin lambda locus Hs.05944 1.7 2.1 5.8 2.0 3.2 3.3 6.0 4.2 2.5 5.0 1.4 3.9 1.7 2.5 5.6 5.0 CD8B1 CD8 antigen, beta polypeptide 1 (p37) Hs.2299 1.4 1.8 5.6 1.3 1.3 1.9 2.0 1.6 1.6 1.4 1.2 1.8 1.3 1.6 1.6 1.4 CCL5 Small inducible cytokine A5 (RANTES) Hs. 41392 0.9 1.1 4.8 1.0 1.3 1.7 2.7 2.8 2.7 2.4 1.0 2.2 2.7 2.7 2.2 2.4 TRA Human T-cell receptor active alpha-chain Hs.74647 1.8 1.7 4.5 1.4 1.9 5.1 4.2 3.1 2.6 2.4 3.0 4.2 1.8 2.6 3.3 2.4 CSF2RA Colony stimulating factor 2 receptor Hs. 82378 1.3 1.9 4.0 1.7 2.4 1.4 3.1 4.3 1.9 2.8 1.1 3.2 3.3 1.9 2.1 2.8 KLRB1 Killer cell lectin-like receptor subfamily B Hs.69824 1.9 2.1 3.9 2.1 1.0 2.6 1.6 1.1 3.6 1.0 1.6 0.9 2.5 3.6 1.7 1.0 CD8A CD8 antigen, alpha polypeptide (p32) Hs.85258 1.6 1.4 3.5 1.4 0.8 1.6 1.7 1.4 2.0 1.1 0.8 1.5 1.6 2.0 1.1 1.1 IGHG3 Immunoglobulin heavy constant gamma 3 Hs.413826 1.6 1.6 3.4 1.0 2.5 2.3 3.2 3.3 2.6 2.8 1.0 3.0 1.8 2.6 5.0 2.8 CD2 CD2 antigen (p50) Hs.89476 1.9 1.3 3.3 1.4 1.3 5.6 4.0 2.0 2.6 1.9 2.0 3.3 3.0 2.6 2.4 1.9 TRGV9 T cell receptor gamma locus Hs.12259 1.2 1.9 3.0 1.8 1.6 3.2 3.2 1.6 2.8 1.8 1.5 1.6 1.6 2.8 2.2 1.8 ITK IL2-inducible T-cell kinase Hs.11576 1.7 1.7 3.0 1.2 1.1 2.6 2.2 1.4 1.7 1.6 1.6 1.6 1.9 1.7 1.5 1.6 SELPLG Selectin P ligand Hs.79283 1.5 1.6 2.8 1.3 1.6 2.9 2.8 3.0 2.6 1.7 1.2 2.6 2.7 2.6 1.5 1.7 VIL2 Villin 2 (ezrin) Hs.155191 1.1 1.8 2.4 1.5 1.8 1.4 2.8 2.2 2.3 2.2 1.4 1.4 1.9 2.2 2.3 1.3 RI58 Retinoic acid- and interferon-inducible protein (58 kD) Hs.27610 0.7 0.9 2.4 0.7 0.8 0.6 0.8 0.7 0.8 0.7 0.7 0.5 0.8 0.8 0.8 0.7 IFNG Interferon gamma Hs.856 1.2 1.6 2.4 1.3 1.1 1.5 1.6 1.2 1.8 1.1 1.1 1.3 1.6 1.8 1.7 1.1 TANK TRAF family member-associated NFKB activator Hs.146847 1.3 1.5 2.3 2.1 1.5 1.5 1.5 1.5 1.5 1.1 1.6 1.3 1.6 1.5 1.7 1.1 TNFRSF1A Tumor necrosis factor receptor (1A) Hs.159 1.6 1.2 2.3 1.1 3.7 0.6 1.9 3.6 1.1 1.5 0.6 1.5 1.2 1.1 1.4 1.5 PADI4 Peptidyl arginine deiminase (type IV) Hs.117232 0.8 1.3 2.2 1.7 1.7 1.1 1.1 2.4 2.0 1.7 1.2 1.2 1.6 2.0 1.3 1.7 Cell Growth/Signal Transduction SFTPA2 Surfactant (pulminory-associated protein A1) Hs.177582 1.2 1.4 3.6 1.2 1.9 1.5 1.8 2.8 2.0 1.9 1.1 1.7 1.8 2.0 1.3 1.9 UBD Diubiquitin Hs.44532 0.9 0.6 3.3 0.5 1.8 4.5 3.4 2.9 2.3 1.4 1.2 1.5 1.5 2.3 1.4 1.4 HOXB5 Homeo box B5 Hs.22554 1.1 1.7 3.2 1.6 1.9 1.1 2.5 3.2 1.1 2.6 0.9 2.0 2.3 1.1 1.8 1.6 BAZ2B Bromodomain adjacent to zinc finger domain, 2B Hs.8383 1.6 1.2 3.0 0.8 1.4 1.0 0.9 2.0 1.0 0.9 0.8 1.4 1.2 1.0 1.0 0.9 AF1Q ALL1-fused gene from chromosome 1q Hs.75823 1.8 2.0 2.6 2.1 4.7 4.6 2.4 2.8 4.5 2.4 3.9 2.5 2.1 4.5 2.3 2.2 ITM2A Integral membrane protein 2A Hs.17109 1.0 1.4 2.6 1.7 1.1 1.8 1.3 1.5 2.7 1.5 1.3 2.3 1.6 2.7 1.5 1.5 ANXA6 Annexin A6 Hs.118796 1.0 1.4 2.5 1.4 2.2 2.0 2.0 5.0 3.3 1.3 0.9 2.3 2.8 3.3 2.0 1.3 SFRS3 Splicing factor, arginine/serine-rich 3 Hs.388623 1.8 1.8 2.5 1.7 2.4 2.1 1.9 2.9 1.5 0.9 1.5 2.1 2.1 1.5 1.2 0.9 AMY2A Amylase, alpha 2A; pancreatic Hs.300280 1.2 1.6 2.5 1.5 1.5 0.9 1.2 1.9 0.8 1.2 0.4 1.0 1.3 0.8 0.8 1.2 KIF22 Kinesin-like 4 Hs.119324 1.4 0.9 2.5 1.7 2.5 3.3 2.1 3.9 1.3 1.1 2.6 2.2 1.2 1.3 1.2 1.1 CAPON Ligand of neuronal nitric oxide synthase Hs.129729 1.7 1.6 2.5 1.2 2.5 0.4 0.8 2.3 1.3 2.0 0.5 2.6 1.4 1.3 2.1 2.0 COX5B Cytochrome c oxidase (subunit Vb) Hs.1342 1.4 1.0 2.5 1.8 1.2 3.8 1.7 1.7 1.6 1.0 2.4 1.2 1.9 1.6 1.7 1.0 LGALS1 Galactoside-binding lectin (galectin 1) Hs.382367 1.6 1.2 2.4 2.0 1.3 3.3 2.9 1.3 1.9 1.0 1.4 1.3 2.5 1.9 2.3 1.0 MBL1P1 Mannose-binding lectin, pseudogene 1 Hs.116218 1.7 1.6 2.4 1.6 1.2 0.6 0.8 1.1 1.4 2.4 0.8 2.1 1.1 1.4 1.3 2.4 GNG3 Guanine nucleotide binding protein Hs.179915 1.5 1.4 2.4 2.1 1.7 1.7 2.4 2.9 1.7 1.2 1.3 2.3 2.0 1.7 1.8 1.2 RBBP4 Retinoblastoma-binding protein 4 Hs.16003 1.2 1.3 2.4 1.7 1.2 1.1 1.0 1.7 1.7 1.2 1.7 1.2 1.4 1.7 1.4 1.2 CHI3L1 Chitinase 3-like 1 (cartilage glycoprotein-39) Hs.75184 0.9 1.6 2.4 1.9 1.5 1.5 1.1 2.7 1.2 1.6 0.9 0.9 2.3 1.2 1.1 1.6 NESG1 Nasopharyngeal epithelium specific protein 1 Hs.158450 0.6 1.5 2.3 1.6 1.1 1.1 0.8 3.2 1.2 1.2 0.7 1.1 2.5 1.2 1.0 1.2 CBLC Cas-Br-M Murine retroviral transforming Hs.156637 0.6 1.5 2.3 1.6 1.2 0.9 0.8 3.7 1.5 1.4 1.2 1.1 3.8 1.5 1.8 1.4 SLC21A6 Solute carrier family 21 Hs.137425 1.4 1.1 2.3 1.1 3.5 0.6 1.8 4.3 1.1 1.3 0.5 1.4 1.0 1.1 1.2 1.3 DSS1 Deleted in split-hand/split-foot 1 region Hs.333495 1.2 1.0 2.3 1.5 1.2 1.2 1.2 1.1 1.8 1.2 2.2 1.0 1.4 1.8 1.5 1.2 BAIAP1 BAI1-associated protein 1 Hs.169441 1.1 1.3 2.3 1.2 1.2 8.0 1.1 1.4 1.8 2.0 0.7 1.4 1.3 1.8 1.3 2.0 PCAF PCAF associated factor 65 beta Hs.26782 1.7 1.7 2.2 1.3 2.2 2.4 2.8 2.1 1.3 0.9 0.8 1.1 1.1 1.3 0.7 0.9 EIF2AK3 Eukaryotic translation initiation factor 2-alpha kinase 3 Hs.102506 1.5 1.4 2.2 1.3 1.0 0.9 0.8 1.1 1.3 1.1 0.8 2.1 1.0 1.3 1.2 1.1 99% confidence interval 1.9 2.1 2.2 2.4 2.1 2.7 2.0 3.3 2.5 2.0 2.6 2.4 2.2 2.5 1.9 2.0 TABLE: Genes induced during the clearance phase of self-limited infection as defined by average expression values. Title Clone description UG cluster Self-limited infection a Persistent infection b Ratio of induction RPS4Y Ribosomal protein S4, Y-linked Hs.180911 12.66 1.64 7.72 GLO1 Glyoxalase I Hs.268849 4.07 0.75 5.41 NPTX1 Neuronal pentraxin I Hs.84154 1.45 0.40 3.59 RI58 Retinoic acid- and interferon-inducible protein (58 kD) Hs.252839 2.40 0.70 3.42 UK114 Translational inhibitor protein p14.5 Hs.18426 2.00 0.59 3.40 AMHR2 Anti-Mullerian hormone receptor, type II Hs.437877 0.97 0.30 3.19 CD8B1 CD8 antigen, beta polypeptide 1 (p37) Hs.2299 5.57 1.76 3.16 KLRB1 Killer cell lectin-like receptor subfamily B, member 1 Hs.169824 3.89 1.24 3.13 APOF Apolipoprotein F Hs.2388 1.00 0.32 3.12 KIAA0855 Golgin-67 Hs.182982 1.60 0.54 2.95 TSNAX Translin-associated factor X Hs.96247 1.81 0.63 2.89 FKBP5 FK506-binding protein 5 Hs.7557 2.69 0.94 2.87 NNMT Nicotinamide N-methyltransferase Hs.364345 2.07 0.76 2.73 NUP153 Nucleoporin 153 kD Hs.146449 1.95 0.72 2.71 SOCS3 Supressor of cytokine signaling 3 Hs.436943 2.54 0.94 2.69 CD3D CD3D antigen, delta polypeptide Hs.95327 6.44 2.42 2.66 CALML3 Calmodulin-like 3 Hs.239600 3.37 1.28 2.63 ARF3 Human ADP-ribosylation factor Hs.22012 1.40 0.54 2.58 GZMA Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) Hs.90708 6.48 2.56 2.53 QUANTITATIVE PCR CONFIRMATION OF SELECTED GENES To confirm the microarray data, TaqMan real-time PCR was performed on selected genes from each analysis. For ISGs, GIP2 and IFIT1 were analyzed. Among the genes identified in Tables 1 and 2 , ILF3, TIA1, ID2 and JUN were selected for quantitative PCR. In addition, serial liver biopsy RNAs from another chimpanzee that developed chronic infection after inoculation with a different HCV strain (H77 1a) were analyzed. The data in general support the microarray results. The ISG expression varied among the chimpanzees, but showed no significant difference between self-limited and chronic infections. The genes (ILF3, TIA1, ID2 and JUN) identified to be different by microarray during the early phase of HCV infection between the two groups were confirmed by quantitative PCR. Their expression levels were 10 to 100-fold higher in X0190 than those of other three chimpanzees. DISCUSSION HCV infection can lead to a high rate of chronicity, with 70–80% of infected persons developing persistent infection [1] . The mechanisms by which HCV establishes chronic infection have been the subject of intense research. Failure of HCV-specific immune response, particularly of the T cells, has been proposed as the cause of chronicity [12] , [13] . Studies in humans and chimpanzees have shown that T cell-mediated immunity is important for viral clearance [14] , [15] . However, the pivotal question remains as to how the host immune response fails during the acute HCV infection so it can no longer control the virus, resulting in persistent infection. Thus it is crucial to define the molecular and cellular mechanisms by which the antiviral host response is activated and regulated during the early stage of acute HCV infection. Furthermore, because the major site of viral tropism is the liver, it is essential to study these events in the liver. One approach to elucidate this complicated process is to study the global gene expression profile in the liver during the acute phase of viral infection, and to discern unique patterns that are associated with either viral clearance or progression to chronic infection. We previously reported the infection of three chimpanzees with an infectious HCV genotype 1b clone; one had acute self-limited infection and the other two developed chronic infection [16] . We reported that regardless of the outcome of infection, peripheral T-cell responses were weak and comparable among the chimpanzees during the course of infection; however, intrahepatic T-cell response was not analyzed [17] . In this study, serial liver biopsies were available in these chimpanzees and were used for cDNA microarray analysis. Analysis of these gene expression patterns revealed that a type I interferon response was induced during the early phase (4–8 weeks) of infection in all chimpanzees regardless of the outcome of infection. Various well-defined interferon stimulated genes were up-regulated in all the liver samples. This observation is consistent with previous studies describing that type I interferon response is rapidly induced in the liver in response to HCV infection [2] , [6] . Interestingly, several genes were specifically induced in the recovered chimpanzee during the early phase of infection but not in those chimpanzees with chronic infection. Two of the genes are interleukin enhancer binding factor 3 (ILF3) and cytotoxic granule-associated RNA binding protein (TIA1). This difference was also confirmed by quantitative RT-PCR ( Fig. 2 ). Both of them are related to cellular immune response and may potentially herald the emergence of a robust T-cell response later. The other genes could be functionally clustered into cell growth/signal transduction pathways. Genes such as FOSB, JUN, JUNB, and ID2 ( Tables 1 and 2 ) are typically associated with the immediate early genes during liver regeneration [18] , [19] . Several studies reported that ID2 (Inhibitor of DNA binding or Differentiation) protein, a helix-loop-helix transcription factor, has important roles in cell growth, differentiation and angiogenesis [20] , [21] . ID2 is also essential for NK lineage commitment from bipotent progenitors of both T and NK cells [22] . Other up-regulated genes including EGR1, ETR101, CDK9 and RelA, are also related to cell growth and proliferation [23] – [25] . Induction of EGR1 and ETR101 is also part of the early proliferative response in the liver. In addition, EGR1 is involved in the induction of FasL in T cells [26] and the ETR101 has been implicated in T cell proliferation and maturation [27] . These two genes might represent the induction of a successful T cell response against HCV in chimpanzee X0190 but not in X0142 and X0234. The induction of these genes may signify the initial phase of hepatocyte injury and proliferation, despite the absence of aminotransferase elevation and liver pathology during this stage of infection. This observation has implication with respect to the induction of adaptive immunity that is important for the subsequent control of viral infection. This pattern of gene expression in the liver may represent a successful “danger signal” that has been proposed to be a trigger for adaptive immunity. The lack of induction of these genes in chimpanzees that progress to chronic infection may actually represent a failure to amplify anti-viral T-cell response. This intriguing hypothesis awaits further studies to clarify the role of these genes during HCV infection. TaqMan real-time PCR was performed as described in Materials and Methods . The y-axis shows the relative unit of a given gene normalized to GAPDH and 18s rRNA. Data are expressed as means±SEM. In all cases, average values obtained during the first eight weeks of infection were compared between recovered (X0190) and chronically infected chimpanzees (X 0234, X0142 and X6412). * P<0.05 , ** P<0.01 , *** P<0.01 , **** P<0.005 . During acute HCV infection, a rapid IFN response limits virus replication and spread in the liver until virus-infected hepatocytes are cleared by specific T-cell immune response [3] . Analysis of gene expression patterns during the viral clearance phase of chimpanzee X0190 reveals the intrahepatic induction of cellular immune response. This is particularly evident with markers of CD8+ T cell response including granzyme A, CD8 antigen, T cell receptors, and interferon-gamma ( Table 3 ). On the other hand, fewer of these genes were induced and at a lower magnitude in chimpanzees with chronic infection. These findings are consistent with a recent study on hepatic gene expression in chimpanzees during acute HCV infection [2] , [6] , and support the importance of T cell immune response in controlling HCV infection [28] – [33] , [12] , [34] , [7] . Other genes that were preferentially induced during the clearance phase are diverse. They do not overlap with those genes induced during the early phase of infection and may represent a more complex array of molecular and cellular events during viral clearance. All these genes returned to baseline expression after viral clearance. In contrast, many ISGs remained elevated in chimpanzees with chronic infection, indicating an ongoing type I IFN response to persistent HCV infection. In this study, molecular profiling of gene expression patterns in chimpanzees with serial liver biopsies during the course of infection provides valuable information on the potential mechanisms of viral clearance and persistence. Although the number of animals is small, we are able to define a unique gene expression pattern associated with viral clearance and demonstrate the potential importance of induction of certain genes in a “successful” anti-HCV response. IFN-stimulated genes (ISGs) are induced similarly regardless of the outcome of infection. Early induction of a set of genes associated with cell proliferation and immune activation appears to be involved in subsequent viral clearance. Furthermore, evidence for a strong intrahepatic induction of cellular immune response in chimpanzees associated with self-limited infection is present. These findings support the importance of T-cell immune response in controlling HCV infection. Additional studies in other chimpanzees or humans with well-characterized course of acute infection are necessary to confirm these observations. MATERIALS AND METHODS Chimpanzees (Pan troglodyte) were housed at the Southwest Foundation for Biomedical Research, an Association for Assessment and Accreditation of Laboratory Animal and Care (AAALAC)-accredited facility, and the study protocol was approved by the Institutional Animal Care and Use Committee at the Foundation and by the Interagency Animal Model Committee at the National Institutes of Health. Three chimpanzees (X0190, X0142 and X0234) were infected with HCV CG1b strain, either by intrahepatic inoculation of HCV RNA or HCV-positive serum, as described previously [16] . One animal X0190 recovered from the infection and the other two (X0142 and X0234) developed chronic infection. The infection courses of all three chimpanzees have been described in detail previously [16] , [17] and summarized in Fig. 1 with time points of liver biopsy. Another chimpanzee X6412 was infected with H77 1a strain and developed chronic infection [35] . Serial liver biopsies of this chimpanzee were provided by Stephen Feinstone of FDA. RNA EXTRACTION AND MICROARRAY EXPRESSION ANALYSIS RNA was isolated from liver biopsies (about 20 mg of liver tissue which gives 10–15 µg of total RNA) of the chimpanzees. Deposition cDNA microarrays containing 8703 features were generated from IMAGE clones (ResGen, Huntsville, AL) as described previously [36] , [37] . Liver biopsies were extracted directly with Trizol (Invitrogen, Carlsbad, CA) and Dounce homogenization. Following chloroform extraction, RNA samples were further purified with RNeasy columns (Qiagen, Valencia, CA). 5–20 µg total RNA was typically isolated from each liver biopsy and 5 µg of RNA was amplified using a RiboAmp protocol (Arcturus Bioscience Inc, Mountain View, California). A single round of amplification yielded approximately 60 µg of polyA-selected RNA, of which 2.5 µg was labeled by using the CyScribe first-strand cDNA and labeling protocol (Amersham/Pharmacia, Piscataway, New Jersey). Briefly, RNA was reverse transcribed to produce Cy-5 labeled cDNA while Cy-3 labeled cDNA was made in a similar manner from pre-infection or uninfected reference liver RNA. Individual Cy-5 labeled samples were mixed with the Cy-3 labeled reference and hybridized overnight at 65°C in an aqueous based hybridization solution. Detailed RNA isolation, labeling and hybridization protocols are available at http://research.nhgri.nih.gov/microarray/ . Slide images were acquired by an Agilent scanner (Agilent Technologies, Palo Alto, CA). Gene assignments and expression data were extracted using the DeArray Suite [38] for IPLab spectrum. The resulting data was downloaded to FileMaker Pro (FileMaker Inc., Santa Clara, CA). Phenotype averaging was performed using the BRB array tools, developed by the Biometrics Research Branch, Division of Cancer Treatment and Diagnosis and available to download on the web: http://linus.nci.nih.gov/BRB-ArrayTools.html REAL-TIME QUANTITATIVE PCR Real-time quantitative PCR was used to confirm the microarray findings. Complementary DNA (cDNA) was synthesized from total RNA (isolated from liver biopsy samples) with First-strand cDNA Synthesis System (Marligen Biosciences, Ijamsville, MD). In addition, we analyzed serial liver biopsy samples from a chronically infected chimpanzee (X1602, infected with genotype 1a H77 strain) by TaqMan PCR quantification of selected genes of interest. The primers and probes used were obtained from Gene Expression Assays (Applied Biosystems, Foster City, CA). Each reaction was performed in duplicate, and all samples were standardized using the internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene and 18S rRNA. Reactions were set up with 12.5 µL TaqMan universal PCR master mix, cDNA template, and 1.25 µL primers and probe mix in a final volume of 25 µL. Reactions were performed on an iCycler iQ Multicolor Real-Time Detection System (Bio-Rad, Hercules, CA) with the following reaction conditions: 95°C for 10 min, followed by 40 cycles of 95°C for 20 sec, 60°C for 1 min, and additional incubation at 68°C for 10 min. STATISTICAL ANALYSIS The overall significance was assessed by 1-way ANOVA and significant difference between groups was assessed by the Student's t -test. REFERENCES [1] Liang TJ Rehermann B Seeff LB Hoofnagle JH 2000 Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132 296 305 [2] Bigger CB Brasky KM Lanford RE 2001 DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 75 7059 66 [3] Bigger CB Guerra B Brasky KM Hubbard G Beard MR 2004 Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 78 13779 92 [4] Helbig KJ Lau DT Semendric L Harley HA Beard MR 2005 Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology 42 702 10 [5] Smith MW Yue ZN Korth MJ Do HA Boix L 2003 Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. Hepatology 38 1458 67 [6] Su AI Pezacki JP Wodicka L Brideau AD Supekova L 2002 Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 99 15669 74 [7] Thimme R Oldach D Chang KM Steiger C Ray SC 2001 Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194 1395 406 [8] Thimme R Bukh J Spangenberg HC Wieland S Pemberton J 2002 Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 99 15661 8 [9] Fernandez J Taylor D Morhardt DR Mihalik K Puig M 2004 Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity. J Virol 78 9782 9 [10] Rahman F Heller T Sobao Y Mizukoshi E Nascimbeni M 2004 Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 40 87 97 [11] Smyk-Pearson S Tester IA Klarquist J Palmer BE Pawlotsky JM 2008 Spontaneous Recovery in Acute Human HCV Infection: Functional T Cell Thresholds and Relative Importance of CD4 Help. J Virol 82 1827 37 [12] Neumann-Haefelin C Blum HE Chisari FV Thimme R 2005 T cell response in hepatitis C virus infection. J Clin Virol 32 75 85 [13] Rehermann B 2007 Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis 27 152 60 [14] Bowen DG Walker CM 2005 Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 946 52 [15] Kaplan DE Sugimoto K Newton K Valiga ME Ikeda F 2007 Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 132 654 66 [16] Thomson M Nascimbeni M Gonzales S Murthy KK Rehermann B 2001 Emergence of a distinct pattern of viral mutations in chimpanzees infected with a homogeneous inoculum of hepatitis C virus. Gastroenterology 121 1226 33 [17] Thomson M Nascimbeni M Havert MB Major M Gonzales S 2003 The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 77 862 70 [18] Natarajan A Wagner B Sibilia M 2007 The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci USA 104 17081 6 [19] Sandoval J Rodriguez JL Tur G Serviddio G Pereda J 2004 RNAPol-ChIP: a novel application of chromatin immunoprecipitation to the analysis of real-time gene transcription. Nucleic Acids Res 32 e88 [20] Damdinsuren B Nagano H Kondo M Yamamoto H Hiraoka N 2005 Expression of Id proteins in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Int J Oncol 26 319 27 [21] Tsunedomi R Iizuka N Yamada-Okabe H Tamesa T Okada T 2006 Identification of ID2 associated with invasion of hepatitis C virus-related hepatocellular carcinoma by gene expression profile. Int J Oncol 29 1445 51 [22] Fujimoto S Ikawa T Kina T Yokota Y 2007 Forced expression of Id2 in fetal thymic T cell progenitors allows some of their progeny to adopt NK cell fate. Int Immunol 19 1175 82 [23] Ahmed-Choudhury J Russell CL Randhawa S Young LS Adams DH 2003 Differential induction of nuclear factor-kappaB and activator protein-1 activity after CD40 ligation is associated with primary human hepatocyte apoptosis or intrahepatic endothelial cell proliferation. Mol Biol Cell 14 1334 45 [24] Dasu MR Cobb JP Laramie JM Chung TP Spies M 2004 Gene expression profiles of livers from thermally injured rats. Gene 327 51 60 [25] Shore SM Byers SA Maury W Price DH 2003 Identification of a novel isoform of Cdk9. Gene 307 175 82 [26] Droin NM Pinkoski MJ Dejardin E Green DR 2003 Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses. Mol Cell Biol 23 7638 47 [27] Ollila J Vihinen M 1998 Stimulation of B and T cells activates expression of transcription and differentiation factors. Biochem Biophys Res Commun 249 475 80 [28] Cooper S Erickson AL Adams EJ Kansopon J Weiner AJ 1999 Analysis of a successful immune response against hepatitis C virus. Immunity 10 439 49 [29] Cucchiarini M Kammer AR Grabscheid B Diepolder HM Gerlach TJ 2000 Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell Immunol 203 111 23 [30] Diepolder HM Zachoval R Hoffmann RM Jung MC Gerlach T 1996 The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C. J Mol Med 74 583 8 [31] Diepolder HM Zachoval R Hoffmann RM Wierenga EA Santantonio T 1995 Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346 1006 7 [32] Gerlach JT Diepolder HM Jung MC Gruener NH Schraut WW 1999 Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 117 933 41 [33] Lechner F Wong DK Dunbar PR Chapman R Chung RT 2000 Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191 1499 512 [34] Takaki A Wiese M Maertens G Depla E Seifert U 2000 Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6 578 82 [35] Major ME Dahari H Mihalik K Puig M Rice CM 2004 Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 39 1709 20 [36] Khan J Bittner ML Chen Y Meltzer PS Trent JM 1999 DNA microarray technology: the anticipated impact on the study of human disease. Biochim Biophys Acta 1423 M17 28 [37] Khan J Simon R Bittner M Chen Y Leighton SB 1998 Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 58 5009 13 [38] Chen Y Dougherty ER Bittner ML 1997 Ratio-based decisions and the quantitative analysis of cDNA microarray images. J Biomed Opt 2 364 374